ActiveMSers Forums  

Go Back   ActiveMSers Forums > ActiveMSers.org Forums > Connect > East North Central Region

Reply
 
Thread Tools Display Modes
  #1  
Old 02-11-2019, 04:40 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is offline
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,492
Default WISCONSIN: Step Therapy Advocacy Day (Mar 6)

Wisconsin Step Therapy Advocacy Day

Date:
Wednesday, March 6, 2019
Time:
9:00 AM - 3:00 PM
Location:
Wisconsin State Capitol
2 East Main Street
Hearing Room 300 NE
Madison, WI 53702

The Wisconsin Step Therapy Coalition invites you to join us on this important day to meet with your state legislators and discuss step therapy legislation. The day will begin with a briefing in the morning followed by legislative visits in the afternoon.

Please register by February 20 at http://bit.ly/WIsteptherapy

If you have any questions, please contact:
Kari Lato at klato@cullarigroup.com or Angie Thies at athies@psoriasis.org

What is step therapy?

Quote:
Step Therapy—Clinical Algorithms, Legislation, and Optimal Prescribing
Michael A. Fischer, MD, Jerry Avorn, MD

JAMA. 2017;317(8):801-802. doi:10.1001/jama.2016.20619

Increasing prescription drug costs impose economic burdens for patients and payers and are reflected in substantial increases in insurance premiums for individuals and employers and budget stress for public programs. One widely used approach to control prescription costs is “step therapy”: requiring patients to try a less expensive drug for a given condition before a more expensive option can be approved. Authorization of the second-line agent may require attestation by the prescriber that the patient took the initial medication and had adverse effects or inadequate clinical benefit. Such clinical algorithms are often sensible and evidence based and can improve the quality of care. But sometimes they are not, because of limited evidence, inadequate attention to the underlying evidence, or an emphasis on cost containment rather than patient outcomes. The economic stakes can be high, because manufacturers’ promotion to both prescribers and patients is usually aimed at encouraging use of more costly second-line agents.
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
  #2  
Old 02-12-2019, 01:12 PM
ActiveMSers's Avatar
ActiveMSers ActiveMSers is offline
Dave @ ActiveMSers
 
Join Date: Jun 2008
Location: Albuquerque, NM
Posts: 3,492
Default

FYI, there is more and more evidence that step therapy may not be the smartest approach in MS, as research is showing that stronger meds at the outset leads to better control of the disease (and potentially lower cost for insurance companies).
__________________
Dave Bexfield
ActiveMSers
Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is Off
Forum Jump


All times are GMT -4. The time now is 09:52 PM.


Powered by vBulletin® Version 3.7.0
Copyright ©2000 - 2019, Jelsoft Enterprises Ltd.
ActiveMSers